Stocks and InvestingStocks and Investing
Tue, January 18, 2022
Mon, January 17, 2022
Fri, January 14, 2022
Thu, January 13, 2022
Wed, January 12, 2022

Andrew Berens Maintained (BPMC) at Buy with Decreased Target to $120 on, Jan 12th, 2022


Published on 2024-10-27 19:14:36 - WOPRAI, Andrew Berens
  Print publication without navigation


Andrew Berens of SVB Leerink, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Decreased Target from $132 to $120 on, Jan 12th, 2022.

Andrew has made no other calls on BPMC in the last 4 months.



There are 3 other peers that have a rating on BPMC. Out of the 3 peers that are also analyzing BPMC, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $111 on, Friday, October 29th, 2021


These are the ratings of the 2 analyists that currently disagree with Andrew


  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021